发布求助
文献互助 智能选刊 最新文献

Medicom Conference Report ASCO GI 2023最新文献

筛选
英文 中文
SWOG 1815, first-ever phase 3 trial in BTC, fails 首个BTC三期临床试验SWOG 1815失败
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/a8a89b60
Robert van den Heuvel
{"title":"SWOG 1815, first-ever phase 3 trial in BTC, fails","authors":"Robert van den Heuvel","doi":"10.55788/a8a89b60","DOIUrl":"https://doi.org/10.55788/a8a89b60","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130361617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy or not in locally advanced oesophageal or junctional cancer? 局部晚期食管癌或结癌是否需要放疗?
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/b0f7c6f2
Robert van den Heuvel
{"title":"Radiotherapy or not in locally advanced oesophageal or junctional cancer?","authors":"Robert van den Heuvel","doi":"10.55788/b0f7c6f2","DOIUrl":"https://doi.org/10.55788/b0f7c6f2","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133403723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer Zolbetuximab联合mFOLFOX6治疗胃癌cldn18.2阳性亚组成功
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/f811f2b0
Robert van den Heuvel
{"title":"Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer","authors":"Robert van den Heuvel","doi":"10.55788/f811f2b0","DOIUrl":"https://doi.org/10.55788/f811f2b0","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115980321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3-year follow-up data confirms benefits of nivolumab plus chemotherapy 3年随访数据证实了纳武单抗联合化疗的益处
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/68722540
Robert van den Heuvel
{"title":"3-year follow-up data confirms benefits of nivolumab plus chemotherapy","authors":"Robert van den Heuvel","doi":"10.55788/68722540","DOIUrl":"https://doi.org/10.55788/68722540","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131187655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality-of-life benefits for tislelizumab in uHCC tislelizumab治疗uHCC的生活质量获益
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/af968169
Robert van den Heuvel
{"title":"Quality-of-life benefits for tislelizumab in uHCC","authors":"Robert van den Heuvel","doi":"10.55788/af968169","DOIUrl":"https://doi.org/10.55788/af968169","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125218823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer? S-1辅助化疗:2期胃癌4个疗程还是8个疗程?
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/318bec28
Robert van den Heuvel
{"title":"S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?","authors":"Robert van den Heuvel","doi":"10.55788/318bec28","DOIUrl":"https://doi.org/10.55788/318bec28","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130829478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC 纳武拉特治疗BTC的安全性可接受，疗效令人鼓舞
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/f6cff4ed
Robert van den Heuvel
{"title":"Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC","authors":"Robert van den Heuvel","doi":"10.55788/f6cff4ed","DOIUrl":"https://doi.org/10.55788/f6cff4ed","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126527026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT ctDNA在监测肛癌患者接受CRT时似乎是有用的
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/caf1e327
Robert van den Heuvel
{"title":"ctDNA appears useful in monitoring patients with anal cancer undergoing CRT","authors":"Robert van den Heuvel","doi":"10.55788/caf1e327","DOIUrl":"https://doi.org/10.55788/caf1e327","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122511172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival following postoperative sorafenib plus TACE in HCC 肝癌患者索拉非尼联合TACE术后生存率提高
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/30fb3fda
Robert van den Heuvel
{"title":"Improved survival following postoperative sorafenib plus TACE in HCC","authors":"Robert van den Heuvel","doi":"10.55788/30fb3fda","DOIUrl":"https://doi.org/10.55788/30fb3fda","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122738352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer LATG/LAPG在1期胃癌中表现出良好的长期疗效
Medicom Conference Report ASCO GI 2023 Pub Date : 2023-03-17 DOI: 10.55788/4d83db52
Robert van den Heuvel
{"title":"LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer","authors":"Robert van den Heuvel","doi":"10.55788/4d83db52","DOIUrl":"https://doi.org/10.55788/4d83db52","url":null,"abstract":"","PeriodicalId":142739,"journal":{"name":"Medicom Conference Report ASCO GI 2023","volume":"144 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133896364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信